```
REGISTERED COMPANY NUMBER: 06996068 (England and Wales)
REGISTERED CHARITY NUMBER: 1132984
```
## **`REPORT OF THE TRUSTEES AND`**
## **`UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`FOR`**
## **`THE INTERNATIONAL CML FOUNDATION`**
```
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2022`**
**----- Start of picture text -----**
Page
Report of the Trustees 1 to 4
Independent Examiner's Report 5
Statement of Financial Activities 6
Balance Sheet 7
Notes to the Financial Statements 8 to 15
**----- End of picture text -----**
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2022`**
```
ThetrusteeswhoarealsodirectorsofthecharityforthepurposesoftheCompaniesAct2006, present
theirreportwiththefinancialstatementsofthecharityfortheyearended31stAugust2022. The
trusteeshaveadoptedtheprovisionsofAccountingandReportingbyCharities:Statement of
RecommendedPracticeapplicabletocharitiespreparingtheiraccountsinaccordancewiththe Financial
Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
```
## **`OBJECTIVES AND ACTIVITIES`**
## **`Objectives and aims`**
```
TheobjectoftheFoundationistheadvancementofhealthbytheimprovementofthetreatmentin all
partsoftheworldofchronicmyeloidleukaemiaandrelateddiseases(together"CML")andfor the
purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-
```
```
(i) to improve clinical practice and disease monitoring in the treatment of CML
```
```
(ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
```
```
(iii)topromoteandsupporttheeducationofanddisseminateknowledgeamongstclinicians, scientists,
health professionals and patients in matters concerning CML
```
```
(iv)topromote,fosterandco-ordinatecollaborationthatisparticularly(butnotexclusively) international
andisnotonlyintheareasandactivitiesofclinicalpracticediseasemonitoringandresearchinto CML
butalsoinanyareaoractivitywhichisormaybeconducivetotheaccelerationofthecontrol and/or
cure of CML
```
```
(v)topromote,setup,establishandsupportandshareandexchangeknowledgewith other
organisations whose objects are similar to these general or primary objects
```
```
(vi)toassistorpromoteanyothercharitablepurposeswhicharerelatedtothesegeneraland primary
objects.
```
## **`Significant activities`**
```
In furtherance of the objects, the Foundation has the following powers:-
```
```
(i) to promote or carry out research
```
```
(ii) to provide advice
```
```
(iii) to give and exchange information and advice and promote learning, study and research
```
```
(iv)tocommission,publish,distributeandcontributetopapers,books,periodicals,reports, leaflets,
posters and other publications of any description
```
```
(v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
```
```
(vi)toraisefundsandtoapplyforandsolicitgrantsfrompharmaceuticalcompaniesanywherein the
world.
```
## **`Public benefit`**
```
TheTrusteeshaveconsideredtheirdutytohavedueregardtopublicbenefitguidancepublishedby the
Commissionandintheiropinion,theforegoingreportontheachievementsand performance
demonstrates that they have complied therewith.
```
```
Page 1
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`ACHIEVEMENT AND PERFORMANCE`**
## **`Charitable activities`**
```
TheiCMLfcontinuedtoleadtheCMLcommunitywiththeCOVID-19&CMLcasecollection,analysis and
treatmentguidance.Thereare3iCMLfinternationalresearchprojectsunderway.Theonline webinars
continueforCOVIDguidanceandotherkeyareasofCMLmanagement.Withthelaunchofthe iCMLf
KnowledgeCentre,aneweducationalprogramspecificallyfornon-academiccentres,theiCMLf continues
to be at the forefront of CML education and enhancing patient management around the world.
```
## **`Global Research Programs`**
```
Covid-19(CANDID)study-Thisremainedasignificantfocusfortheyear.Thecompleted dataset
included1,050casesfrom900physiciansin58countries.thedataiswidelyrespectedwith4 further
presentations at international conferences.
```
## **`Cure Consortium`**
```
iCMLfTreatmentFreeRemissionAlliance-GlobalTFRregistrybeganinFebruary2022.24sitesfrom 16
countries and 2.900 potential datasets. Site initiation remains ongoing.
```
```
iCMLfGenomicAlliance-TheiCMLfgenomicsproject'ClonalHierarchyinCML'datauploadis underway.
12 sites from 10 countries participating.
```
## **`Online CML Education`**
```
iCMLfClinicalConversations-9discussionswith16expertsfrom10countrieswithover300 live
participants and 3,000 online participants.
```
## **`iCMLf Knowledge Centre`**
```
TheKnowledgeCentreisaninteractive,onlineresourceprovidingeducationalcontentforholistic CML
patient management. 33 speaker from 16 countries with 1,600 users.
```
## **`FINANCIAL REVIEW`**
## **`Financial position`**
```
The financial position of the International CML Foundation remains solid.
```
## **`Principal funding sources`**
```
TheiCMLfworkscloselywithindustryandcommunitypartnerstosecureunrestrictedgrants and
sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.
```
## **`Reserves policy`**
```
Thereservesattheyearendwere£328,540(2021-£305,347).ItisthepolicyoftheTrustees to
maintainsufficientreservestoensurethedaytodayrunningoftheFoundation.Thelevelofreserves and
currentfinancialcommitmentsarereviewedregularlyatTrustees'meetings.TheFoundationplansto hold
aminimumof£150,000asreservefunding.Thisistheamountforthefoundationtooperate without
further income/outgoings for one year.
```
## **`FUTURE PLANS`**
```
WhilemaintainingtheexpertbestpracticeandeducationinitiativesoftheFoundation,weaimto harness
globalnetworkoftheiCMLftoenhanceresearchintopotentialcuresforCML.TheiCMLf Genomics
AlliancewillaccessthewealthofgenomicinformationthatisgeneratedinlocalCMLresearchprojects by
facilitatingdataassimilationandsamplesexchangesthroughaninternationaldatacollection platform.
Combiningmanydatasetsandfacilitatingglobalcollaborativestudieswillenableustodevelopa baseline
predictor of adverse outcomes.
```
```
TheiCMLfTFRAlliancelookstodefinebiomarkersfortreatmentdiscontinuationandafunctionalcure of
CML.
```
```
TheCMLandCOVID-19retrospectivecaseanalysiswillprovidedataforphysicianstobase treatment
decisions on as the pandemic continues.
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
## **`Governing document`**
```
Thecharityiscontrolledbyitsgoverningdocument,adeedoftrust,andconstitutesalimited company,
limited by guarantee, as defined by the Companies Act 2006.
```
```
Page 2
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
## **`Recruitment and appointment of new trustees`**
```
ThepowerofappointingneworadditionalTrusteesisvestedintheexistingTrustees.Prior to
appointment,newTrusteeswouldbeintroducedtotheworkingsoftheFoundationandadvisedof their
responsibilities.
```
## **`Organisational structure`**
```
The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.
```
```
Theoperationalteam;CommunicationsDirector,CommunicationsManager,DigitalMediaOfficer, and
ERSAP Program Coordinator, report to the chief executive.
```
```
Strategicdirection,financialreviewandbudgetapprovalaresetatanannualiCMLfdirectorsmeeting in
September/October each year. Further directors planning and discussion meetings are held quarterly.
```
```
Strategicplanningisassistedwithanannualadvisorsmeeting.Thisincludesthethirteen physicians,
scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.
```
```
Theoperationalteammeetsevery6-8weeks.Thecommunicationsdirector/communications manager
meetbiweeklywiththechiefexecutiverespectivelyandtheprogramcoordinatorandchief executive
meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.
```
```
Decisionsareescalatedfromtheoperationalteamtothechiefexecutive,iCMLfChairmanand iCMLf
Board of Directors according to scale and impact.
```
## **`REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number`**
```
06996068 (England and Wales)
```
## **`Registered Charity number`**
```
1132984
```
## **`Registered office`**
```
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
## **`Trustees`**
```
Professor T P Hughes
Professor M Baccarani Professor (resigned 20/12/2021)
Professor J Cortes Professor
```
```
Professor B Druker Professor
Professor A Hochhaus Professor
Professor J Radich Professor
Professor C Schiffer Professor
Professor J F Apperley DM FRCP/Path Professor
Professor M Mauro Professor
Professor G Saglio Professor
```
## **`Company Secretary`**
```
Ms N C Evans
```
## **`Independent Examiner`**
```
R Appleyard FCA
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
```
Page 3
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`REFERENCE AND ADMINISTRATIVE DETAILS`**
## **`Bankers`**
```
HSBC Bank, 152 Portobello Road, London, W11 2EA
```
```
ThisreporthasbeenpreparedinaccordancewiththespecialprovisionsofPart15oftheCompanies Act
2006 relating to small companies.
```
```
Approved by order of the board of trustees on 11th May 2023 and signed on its behalf by:
```
```
Professor T P Hughes - Trustee
```
```
Page 4
```
```
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`Independent examiner's report to the trustees of The International CML Foundation ('the Company')`**
```
IreporttothecharitytrusteesonmyexaminationoftheaccountsoftheCompanyfortheyear ended
31st August 2022.
```
## **`Responsibilities and basis of report`**
```
Asthecharity'strusteesoftheCompany(andalsoitsdirectorsforthepurposesofcompanylaw)you are
responsibleforthepreparationoftheaccountsinaccordancewiththerequirementsoftheCompanies Act
2006 ('the 2006 Act').
```
```
HavingsatisfiedmyselfthattheaccountsoftheCompanyarenotrequiredtobeauditedunderPart16 of
the2006Actandareeligibleforindependentexamination,Ireportinrespectofmyexaminationof your
charity'saccountsascarriedoutunderSection145oftheCharitiesAct2011('the2011Act').In carrying
outmyexaminationIhavefollowedtheDirectionsgivenbytheCharityCommissionunder Section
145(5) (b) of the 2011 Act.
```
## **`Independent examiner's statement - matters of concern identified`**
```
I have completed my examination.
```
```
IdrawattentiontoNote10oftheaccounts,regardingthebalanceoffundsheldbyPaypal. Whilst
nothinghascometomyattentiontoindicatethatthebalanceshownintheaccountsisincorrect,it has
notbeenpossibletoverifythebalanceoffundsheldinthePaypalaccountaspartofmyexamination due
to the fact that the charity is currently unable to access the account.
```
```
Iconfirmthatnoothermattershavecometomyattentioninconnectionwiththeexaminationgiving me
reasonable cause to believe that in any material respect:
```
`1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or`
`2. the accounts do not accord with those records; or`
`3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; and`
`4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).`
```
Iconfirmthattherearenoothermatterstowhichyourattentionshouldbedrawntoenablea proper
understanding of the accounts to be reached.
```
```
R Appleyard FCA
```
```
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE
```
```
16th May 2023
```
```
Page 5
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST AUGUST 2022`**
|`Unrestricted`
`funds`
`Notes`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
**`119,414`**
`Other trading activities`
`2`
**`279`**
`Other income`
`3`
**`23,495`**
**`Total`**
**`143,188`**
**`EXPENDITURE ON`**
**`Charitable activities`**
`Diagnosis & testing`
**`-`**
`Scientific meetings`
**`5,926`**
`ICMLF Forum`
**`17`**
`Communications`
**`31,816`**
`Fundraising`
**`12,448`**
`Cure Consortium`
**`14,102`**
`Candid`
**`-`**
`Knowledge Centre`
**`(20,073)`**
`Conversations`
**`23,403`**
`Other`
**`20,242`**
**`Total`**
**`87,881`**
**`NET INCOME/(EXPENDITURE)`**
**`55,307`**
**`RECONCILIATION OF FUNDS`**
`Total funds brought forward`
**`156,702`**
**`TOTAL FUNDS CARRIED FORWARD`**
**`212,009`**|`Restricted`
`funds`
`£`
**`66,043`**
**`-`**
**`-`**
**`66,043`**
**`11,784`**
**`-`**
**`-`**
**`372`**
**`-`**
**`-`**
**`23,304`**
**`61,138`**
**`1,559`**
**`-`**
**`98,157`**
**`(32,114)`**
**`148,645`**
**`116,531`**|**`2022`**
**`Total`**
**`funds`**
**`£`**
**`185,457`**
**`279`**
**`23,495`**
**`209,231`**
**`11,784`**
**`5,926`**
**`17`**
**`32,188`**
**`12,448`**
**`14,102`**
**`23,304`**
**`41,065`**
**`24,962`**
**`20,242`**
**`186,038`**
**`23,193`**
**`305,347`**
**`328,540`**|`2021`
`Total`
`funds`
`£`
`75,107`
`-`
`(5,904)`
`69,203`
`-`
`696`
`3,402`
`29,031`
`8,913`
`5,147`
`35,113`
`21,529`
`28,938`
`13,891`
`146,660`
`(77,457)`
`382,804`
`305,347`|
|---|---|---|---|
```
The notes form part of these financial statements
```
```
Page 6
```
```
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
```
## **`BALANCE SHEET`**
## **`31ST AUGUST 2022`**
|`Unrestricted`
`funds`
`Notes`
`£`
**`CURRENT ASSETS`**
`Debtors`
`10`
**`102,793`**
`Cash at bank and in hand`
**`113,584`**
**`216,377`**
**`CREDITORS`**
`Amounts falling due within one year`
`11`
**`(4,368)`**
**`NET CURRENT ASSETS`**
**`212,009`**
**`TOTAL ASSETS LESS CURRENT`**
**`LIABILITIES`**
**`212,009`**
**`NET ASSETS`**
**`212,009`**
**`FUNDS`**
`12`
`Unrestricted funds`
`Restricted funds`
**`TOTAL FUNDS`**|`Restricted`
`funds`
`£`
**`-`**
**`116,531`**
**`116,531`**
**`-`**
**`116,531`**
**`116,531`**
**`116,531`**|**`2022`**
**`Total`**
**`funds`**
**`£`**
**`102,793`**
**`230,115`**
**`332,908`**
**`(4,368)`**
**`328,540`**
**`328,540`**
**`328,540`**
**`212,009`**
**`116,531`**
**`328,540`**|`2021`
`Total`
`funds`
`£`
`86,793`
`222,826`
`309,619`
`(4,272)`
`305,347`
`305,347`
`305,347`
`156,702`
`148,645`
`305,347`|
|---|---|---|---|
```
ThecharitablecompanyisentitledtoexemptionfromauditunderSection477oftheCompaniesAct 2006
for the year ended 31st August 2022.
```
```
Themembershavenotrequiredthecompanytoobtainanauditofitsfinancialstatementsforthe year
ended 31st August 2022 in accordance with Section 476 of the Companies Act 2006.
```
```
The trustees acknowledge their responsibilities for
```
- `(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and`
- `(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.`
```
Thesefinancialstatementshavebeenpreparedinaccordancewiththeprovisionsapplicableto charitable
companies subject to the small companies regime.
```
```
ThefinancialstatementswereapprovedbytheBoardofTrusteesandauthorisedforissue on
11th May 2023 and were signed on its behalf by:
```
```
T P Hughes - Trustee
```
```
The notes form part of these financial statements
```
```
Page 7
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`1. ACCOUNTING POLICIES`**
## **`Basis of preparing the financial statements`**
```
Thefinancialstatementsofthecharitablecompany,whichisapublicbenefitentityunderFRS 102,
havebeenpreparedinaccordancewiththeCharitiesSORP(FRS102)'Accountingand Reporting
byCharities:StatementofRecommendedPracticeapplicabletocharitiespreparingtheir accounts
inaccordancewiththeFinancialReportingStandardapplicableintheUKandRepublicof Ireland
(FRS102)(effective1January2019)',FinancialReportingStandard102'TheFinancial Reporting
StandardapplicableintheUKandRepublicofIreland'andtheCompaniesAct2006.The financial
statements have been prepared under the historical cost convention.
```
## **`Income`**
```
Items of income are recognised and included in the accounts when all of the following criteria
are met:
```
- `The charity or its subsidiary have entitlement to the funds;`
- `any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;`
- `there is sufficient certainty that receipt of the income is considered probable; and`
- `the amount can be measured reliably.`
## **`Expenditure`**
```
Liabilitiesarerecognisedasexpenditureassoonasthereisalegalorconstructive obligation
committingthecharitytothatexpenditure,itisprobablethatatransferofeconomicbenefits will
berequiredinsettlementandtheamountoftheobligationcanbemeasuredreliably. Expenditure
isaccountedforonanaccrualsbasisandhasbeenclassifiedunderheadingsthataggregate all
costrelatedtothecategory.Wherecostscannotbedirectlyattributedtoparticularheadings they
have been allocated to activities on a basis consistent with the use of resources.
```
## **`Debtors`**
```
Debtorsarerecognisedatthesettlementamountdueafteranytradediscount offered.
Prepayments are valued at the amount prepaid after taking account of any trade discounts due.
```
## **`Creditors and provisions`**
```
Creditorsandprovisionsarerecognisedwherethecharityhasapresentobligationresultingfrom a
pasteventthatwillprobablyresultinthetransferoffundstoathirdpartyandtheamountdue to
settletheobligationcanbemeasuredorestimatedreliably.Creditorsandprovisionsare normally
recognised at their settlement amount after allowing for any trade discounts due.
```
## **`Taxation`**
```
The charity is exempt from corporation tax on its charitable activities.
```
## **`Fund accounting`**
```
Unrestrictedfundscanbeusedinaccordancewiththecharitableobjectivesatthediscretionof the
trustees.
```
```
Restrictedfundscanonlybeusedforparticularrestrictedpurposeswithintheobjectsof the
charity.Restrictionsarisewhenspecifiedbythedonororwhenfundsareraisedfor particular
restricted purposes.
```
```
Furtherexplanationofthenatureandpurposeofeachfundisincludedinthenotestothe financial
statements.
```
## **`Foreign currencies`**
```
Assetsandliabilitiesinforeigncurrenciesaretranslatedintosterlingattheratesof exchange
rulingatthebalancesheetdate.Transactionsinforeigncurrenciesaretranslatedintosterling at
therateofexchangerulingatthedateoftransaction.Exchangedifferencesaretakeninto account
in arriving at the operating result and are shown as other income.
```
```
continued...
```
```
Page 8
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2022
```
## **`2. OTHER TRADING ACTIVITIES`**
```
The iCMLf request donations through the iCMLf website.
```
## **`3.`**
## **`OTHER INCOME`**
```
Otherincomeconsistsoftheprofitonforeigncurrencyexchangeinaccordancewiththe accounting
policy on foreign exchange transactions.
```
## **`4. SUPPORT COSTS`**
|`Management`
`fees`
`Finance`
`Other`
`£`
`£`
`£`
`Other resources`
`expended`
**`17,586`**
**`268`**
**`567`**
`Diagnosis & testing`
**`11,784`**
**`-`**
**`-`**
`Scientific meetings`
**`1,785`**
**`-`**
**`-`**
`Communications`
**`27,990`**
**`-`**
**`-`**
`Fundraising`
**`5,034`**
**`17`**
**`1,966`**
`Cure Consortium`
**`10,926`**
**`-`**
**`-`**
`Candid`
**`22,403`**
**`-`**
**`-`**
`Knowledge Centre`
**`36,736`**
**`-`**
**`-`**
`Conversations`
**`23,501`**
**`-`**
**`-`**
**`157,745`**
**`285`**
**`2,533`**
`Support costs, included in the above, are as follows:`
**`Management fees`**
`Other`
`resources`
`expended`
`£`
`Management & admin`
**`17,586`**
`Communications Fundraising`
`£`
`£`
`Management & admin`
**`27,990`**
**`5,034`**
`Knowledge`
`Centre`
`Conversations`
`£`
`£`
`Management & admin`
**`36,736`**
**`23,501`**|`Governance`
`costs`
`£`
**`1,821`**
**`-`**
**`-`**
**`1,456`**
**`-`**
**`-`**
**`-`**
**`1,456`**
**`1,456`**
**`6,189`**
`Diagnosis`
`& testing`
`£`
**`11,784`**
`Cure`
`Consortium`
`£`
**`10,926`**
**`2022`**
`Total`
`activities`
**`£`**
**`157,745`**|`Totals`
`£`
**`20,242`**
**`11,784`**
**`1,785`**
**`29,446`**
**`7,017`**
**`10,926`**
**`22,403`**
**`38,192`**
**`24,957`**
**`166,752`**
`Scientific`
`meetings`
`£`
**`1,785`**
`Candid`
`£`
**`22,403`**
`2021`
`Total`
`activities`
`£`
**`132,913`**|
|---|---|---|
```
continued...
```
```
Page 9
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`4. SUPPORT COSTS - continued Finance`**
## **`5.`**
|**`SUPPORT COSTS - continued`**
**`Finance`**||||||||
|---|---|---|---|---|---|---|---|
|||||**`2022`**||`2021`||
||`Other`|||||||
||`resources`|||`Total`||`Total`||
||`expended`|`Fundraising`||`activities`||`activities`||
||`£`|`£`||**`£`**||`£`||
|`Bank charges`|**`268`**|**`17`**||**`285`**||**`395`**||
|**`Other`**||||||||
|||||**`2022`**||`2021`||
||`Other`|||||||
||`resources`|||`Total`||`Total`||
||`expended`|`Fundraising`||`activities`||`activities`||
||`£`|`£`||**`£`**||`£`||
|`Sundry office costs`|**`567`**|**`1,966`**||**`2,533`**||**`2,631`**||
|**`Governance costs`**||||||||
|||`Other`||||||
|||`resources`||||`Knowledge`||
|||`expended`|`Communications`|||`Centre`||
|||`£`||`£`||`£`||
|`Accountancy - Independent`||||||||
|`examination fee`||**`-`**||**`1,456`**||**`1,456`**||
|`Legal and Professional fees`||**`1,821`**|||**`-`**||**`-`**|
|||**`1,821`**||**`1,456`**||**`1,456`**||
|||||**`2022`**||`2021`||
|||||`Total`||`Total`||
|||`Conversations`||`activities`||`activities`||
|||`£`||**`£`**||`£`||
|`Accountancy - Independent`||||||||
|`examination fee`||**`1,456`**||**`4,368`**||**`4,242`**||
|`Legal and Professional fees`||**`-`**||**`1,821`**|||**`-`**|
|||**`1,456`**||**`6,189`**||**`4,242`**||
|**`NET INCOME/(EXPENDITURE)`**||||||||
|`Net income/(expenditure) is stated after charging/(crediting):`||||||||
|||||**`2022`**||`2021`||
|||||**`£`**||`£`||
|`Accountancy - Independent examination fee`||||**`4,368`**||`4,242`||
```
continued...
```
```
Page 10
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2022
```
## **`6. TRUSTEES' REMUNERATION AND BENEFITS`**
```
Therewerenotrustees'remunerationorotherbenefitsfortheyearended31stAugust2022 nor
for the year ended 31st August 2021.
```
## **`Trustees' expenses`**
```
Therewerenotrustees'expensespaidfortheyearended31stAugust2022norforthe year
ended 31st August 2021.
```
## **`7. STAFF COSTS`**
```
The average monthly number of employees during the year was as follows:
```
||**`2022`**|`2021`|
|---|---|---|
|`Charitable activities`|**`4`**|`4`|
```
Thenumberofemployeeswhoseemployeebenefits(excludingemployerpensioncosts) exceeded
£60,000 was:
```
## **`8.`**
|`£80,001 - £90,000`
**`COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES`**
`Unrestricted`
`funds`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
`8,459`
`Other income`
`(5,904)`
**`Total`**
`2,555`
**`EXPENDITURE ON`**
**`Charitable activities`**
`Scientific meetings`
`696`
`ICMLF Forum`
`3,402`
`Communications`
`1,414`
`Fundraising`
`5,818`
`Cure Consortium`
`-`
`Candid`
`39`
`Knowledge Centre`
`21,529`
`Conversations`
`27,098`
`Other`
`13,891`
**`Total`**
`73,887`
**`NET INCOME/(EXPENDITURE)`**
`(71,332)`
**`RECONCILIATION OF FUNDS`**
`Total funds brought forward`
`228,033`||**`2022`**
**`1`**
`Restricted`
`funds`
`£`
`66,648`
`-`
`66,648`
`-`
`-`
`27,617`
`3,095`
`5,147`
`35,074`
`-`
`1,840`
`-`
`72,773`
`(6,125)`
`154,771`|`2021`
`1`
`Total`
`funds`
`£`
`75,107`
`(5,904)`
`69,203`
`696`
`3,402`
`29,031`
`8,913`
`5,147`
`35,113`
`21,529`
`28,938`
`13,891`
`146,660`
`(77,457)`
`382,804`|
|---|---|---|---|
|||||
```
continued...
```
```
Page 11
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2022
```
## **`8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued`**
|`Unrestricted`
`funds`
`£`
**`TOTAL FUNDS CARRIED FORWARD`**
`156,701`|`Restricted`
`funds`
`£`
`148,646`|`Total`
`funds`
`£`|
|---|---|---|
|||`305,347`|
## **`9. VOLUNTEERS`**
```
Thecharityheavilyreliesuponthemanymedicalprofessionalswhodonatetheirtimetohelp run
thevariouscharitableactivitiesundertaken.Itisnotpossibletoaccuratelycalculatethevalue of
theservicescontributedbythesevolunteersandthereforethenumbersdonotreflecteither the
income or expenditure, however it is thought to be in the region of £230,000.
```
## **`10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
||**`2022`**|`2021`|
|---|---|---|
||**`£`**|`£`|
|`Other debtors`|**`102,793`**|`86,793`|
```
Includedwithinotherdebtorsisabalanceof£88,015inrespectoffundsheldbyPaypal.As a
resultofachangeofpersonnel,theaccountaccessisbeingtransferredbyPaypal,anduntil this
process has been completed the charity cannot transfer or use these funds.
```
## **`11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
|`Accrued expenses`
**`MOVEMENT IN FUNDS`**
**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Pfizer`
`Novartis Patient`
`Novartis Pharma AG`
**`TOTAL FUNDS`**|`At 1/9/21`
`£`
**`156,702`**
**`123,410`**
**`24,863`**
**`372`**
**`-`**
**`148,645`**
**`305,347`**|**`2022`**
**`£`**
**`4,368`**
`Net`
`movement`
`in funds`
`£`
**`55,307`**
**`(11,784)`**
**`(24,863)`**
**`(372)`**
**`4,905`**
**`(32,114)`**
**`23,193`**|`2021`
`£`
`4,272`
`At`
`31/8/22`
`£`
**`212,009`**
**`111,626`**
**`-`**
**`-`**
**`4,905`**|`2021`
`£`
`4,272`|
|---|---|---|---|---|
||||**`116,531`**||
||||**`328,540`**||
## **`12. MOVEMENT IN FUNDS`**
```
continued...
```
```
Page 12
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2022
```
## **`12. MOVEMENT IN FUNDS - continued`**
```
Net movement in funds, included in the above are as follows:
```
|**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Pfizer`
`Novartis Patient`
`Novartis Pharma AG`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
**`143,188`**
**`-`**
**`-`**
**`-`**
**`66,043`**
**`66,043`**
**`209,231`**|`Resources`
`expended`
`£`
**`(87,881)`**
**`(11,784)`**
**`(24,863)`**
**`(372)`**
**`(61,138)`**
**`(98,157)`**
**`(186,038)`**|`Movement`
`in funds`
`£`
**`55,307`**
**`(11,784)`**
**`(24,863)`**
**`(372)`**
**`4,905`**
**`(32,114)`**
**`23,193`**|
|---|---|---|---|
## **`Comparatives for movement in funds`**
|**`Unrestricted funds`**
`General fund`
`Cepheid`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Pfizer`
`Novartis Killi Climb`
`Novartis Patient`
**`TOTAL FUNDS`**|`At 1/9/20`
`£`
`224,118`
`3,915`
`228,033`
`123,410`
`23,118`
`8,243`
`-`
`154,771`
`382,804`|`Net`
`movement`
`in funds`
`£`
`(67,416)`
`(3,915)`
`(71,331)`
`-`
`1,745`
`(8,243)`
`372`
`(6,126)`
`(77,457)`|`At`
`31/8/21`
`£`
`156,702`
`-`|
|---|---|---|---|
||||`156,702`
`123,410`
`24,863`
`-`
`372`|
||||`148,645`|
||||`305,347`|
```
continued...
```
```
Page 13
```
```
THE INTERNATIONAL CML FOUNDATION
```
## **`NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2022`**
## **`12. MOVEMENT IN FUNDS - continued`**
```
Comparative net movement in funds, included in the above are as follows:
```
|**`Unrestricted funds`**
`General fund`
`Cepheid`
**`Restricted funds`**
`Takeda Oncology`
`Pfizer`
`Novartis Killi Climb`
`Novartis Patient`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
`2,555`
`-`
`2,555`
`29,457`
`36,819`
`-`
`372`
`66,648`
`69,203`|`Resources`
`expended`
`£`
`(69,971)`
`(3,915)`
`(73,886)`
`(29,457)`
`(35,074)`
`(8,243)`
`-`
`(72,774)`
`(146,660)`|`Movement`
`in funds`
`£`
`(67,416)`
`(3,915)`
`(71,331)`
`-`
`1,745`
`(8,243)`
`372`
`(6,126)`
`(77,457)`|
|---|---|---|---|
```
A current year 12 months and prior year 12 months combined position is as follows:
```
|**`Unrestricted funds`**
`General fund`
`Cepheid`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Pfizer`
`Novartis Killi Climb`
`Novartis Pharma AG`
**`TOTAL FUNDS`**|`At 1/9/20`
`£`
`224,118`
`3,915`
`228,033`
`123,410`
`23,118`
`8,243`
`-`
`154,771`
`382,804`|`Net`
`movement`
`in funds`
`£`
`(12,109)`
`(3,915)`
`(16,024)`
`(11,784)`
`(23,118)`
`(8,243)`
`4,905`
`(38,240)`
`(54,264)`|`At`
`31/8/22`
`£`
`212,009`
`-`|
|---|---|---|---|
||||`212,009`
`111,626`
`-`
`-`
`4,905`|
||||`116,531`|
||||`328,540`|
```
continued...
```
```
Page 14
```
```
THE INTERNATIONAL CML FOUNDATION
```
```
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2022
```
## **`12. MOVEMENT IN FUNDS - continued`**
```
Acurrentyear12monthsandprioryear12monthscombinednetmovementinfunds,included in
the above are as follows:
```
|**`Unrestricted funds`**
`General fund`
`Cepheid`
**`Restricted funds`**
`Novartis Pharmaceuticals Corporation`
`Takeda Oncology`
`Pfizer`
`Novartis Killi Climb`
`Novartis Patient`
`Novartis Pharma AG`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
`145,743`
`-`
`145,743`
`-`
`29,457`
`36,819`
`-`
`372`
`66,043`
`132,691`
`278,434`|`Resources`
`expended`
`£`
`(157,852)`
`(3,915)`
`(161,767)`
`(11,784)`
`(29,457)`
`(59,937)`
`(8,243)`
`(372)`
`(61,138)`
`(170,931)`
`(332,698)`|`Movement`
`in funds`
`£`
`(12,109)`
`(3,915)`
`(16,024)`
`(11,784)`
`-`
`(23,118)`
`(8,243)`
`-`
`4,905`
`(38,240)`
`(54,264)`|
|---|---|---|---|
## **`13. RELATED PARTY DISCLOSURES`**
```
There were no related party transactions for the year ended 31st August 2022.
```
```
Page 15
```